Latest Papillary thyroid cancer Stories
Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumor recurrence and cancer-related death after surgery.
Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women.
Papillary carcinoma is the most common type of thyroid cancer, and about one fourth of these carcinomas have mutations in the BRAF gene.
Papillary carcinoma is the most common form of thyroid cancer.
Surgical approaches that reduce incision size and recovery time from thyroid surgery work well in children, physician-scientists report.
After a phase 2 trial, 49 percent of patients with advanced differentiated thyroid cancers responded to treatment using a drug designed to stop tumor blood vessel growth.
Individuals with papillary thyroid cancer that has not spread beyond the thyroid gland appear to have favorable outcomes regardless of whether they receive treatment within the first year after diagnosis.
People living in volcanic areas may be at a higher risk for thyroid cancer, according to a new study published online November 5 in the Journal of the National Cancer Institute.
ORLANDO, May 18 /PRNewswire-USNewswire/ -- A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates. At the annual meeting of the American Society of Clinical Oncology (ASCO), Mayo investigators report that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.